| Document |
Document Title |
|
WO/2024/075784A1 |
One embodiment of the present invention provides a method for selecting an additive capable of inhibiting a nitrosation reaction. Another embodiment of the present invention provides a preparation prevented from the generation of a nitro...
|
|
WO/2024/041634A1 |
The present disclosure provides a compound having USP1 inhibitory activity or functionality and a pharmaceutically acceptable salt thereof. The present disclosure further provides a pharmaceutical composition comprising the compound repr...
|
|
WO/2024/016826A1 |
The present invention relates to the field of organic synthetic medicines, and in particular, to a 6-position substituted 3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide compound, having a general formula as follows: (I). The 6-positio...
|
|
WO/2024/000060A1 |
The present invention provides novel salts of belumosudil (I) and crystalline forms thereof. Specific salts of belumosudil provided by the present invention include L-malate, acesulfamate, fumarate, maleate, isethionate, malonate, edisyl...
|
|
WO/2023/216910A1 |
Provided in the present invention is a new substituted bicyclic heteroaryl compound as represented by formula (A), or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate ...
|
|
WO/2023/215220A1 |
The present disclosure provides, in part, compounds of formula (I), or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein; pharmaceutical compositions comprising the compounds; a...
|
|
WO/2023/143389A1 |
The present disclosure relates to a fused heterocyclic compound, a preparation method therefor, and a medical application thereof. Specifically, the present disclosure relates to a fused heterocyclic compound represented by general formu...
|
|
WO/2023/123405A1 |
The present application discloses a method for processing a hydrolysis reaction product containing acesulfame, comprising the following steps: step 1, letting the hydrolysis reaction product containing acesulfame stand and separate into ...
|
|
WO/2023/123406A1 |
Disclosed in the present application is a method for preparing acesulfame potassium. The method comprises the following steps: step 1, mixing sulfamic acid and an amine for reaction to prepare amino sulfamate; step 2, reacting the amino ...
|
|
WO/2023/123403A1 |
The present application discloses a method for the continuous preparation of an acesulfame intermediate. Step 1: mixing and reacting sulfamic acid and an amine to obtain a sulfamic acid amine salt; step 2: reacting the sulfamic acid amin...
|
|
WO/2023/123356A1 |
The present application discloses a method for hydrolytic preparation of acesulfame, which comprises the following steps: step 1: mixing and reacting sulfamic acid and triethylamine to obtain sulfamic acid triethylamine salt; step 2: rea...
|
|
WO/2023/123404A1 |
The present application discloses an industrial preparation method for acetoacetyl-N-sulfamate, the acetyl-N-sulfamate being used as an intermediate for synthesizing Acesulfame-K. The method comprises the following steps: step 1, dissolv...
|
|
WO/2023/087101A1 |
Sulfonate salts of ruxolitinib and crystalline forms thereof, pharmaceutical compositions comprising these salts and crystalline forms thereof, and the use of these salts in the treatment of acute graft versus host disease, polycythemia ...
|
|
WO/2023/083297A1 |
Provided are small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. Further provided are methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating disea...
|
|
WO/2023/064058A1 |
Compounds of formula I, that modulate DCAF15 and induce RBM39 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity ...
|
|
WO/2023/043803A1 |
Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclose...
|
|
WO/2023/039068A1 |
The present disclosure provides intermediates for the synthesis of peptide nucleic acid (PNA) backbones and monomers, such as cyclic intermediates, and methods of making the same.
|
|
WO/2022/246862A1 |
Provided is a potassium acetylsulfonate composition, comprising potassium acetylsulfonate and a chloride thereof, wherein the content of the chloride is less than 300 ppm. The composition is prepared by the following method: adding triet...
|
|
WO/2022/246865A1 |
Provided is a preparation method for acesulfame potassium, which comprises: a pretreatment step, involving: treating an acetoacetamide-N-sulfonic acid triethylamine salt solution with a weakly alkaline inorganic substance to obtain an in...
|
|
WO/2022/246861A1 |
A preparation method for acesulfame potassium, comprising: adding triethylamine to a sulfamic acid solution, and carrying out an amination reaction to generate a sulfamic acid ammonium salt solution; adding diketene to the obtained sulfa...
|
|
WO/2022/246867A1 |
Provided is an acesulfame potassium preparation method, comprising: using an acetoacetamide-N-sulfonic acid triethylamine salt solution as a working fluid, and dissolving sulfur trioxide in a solvent to form a cyclizing agent solution as...
|
|
WO/2022/246868A1 |
Provided is a preparation method for acesulfame potassium, comprising: a salt-forming step: separating a sulfonation cyclization product solution into an organic phase and an inorganic phase, and adding an ethanolic solution of potassium...
|
|
WO/2022/246869A1 |
A method for preparing acesulfame potassium, the method comprising: pressing an acetoacetamide-N-sulfonic acid triethylamine salt solution and a cyclizing agent solution into a Venturi reactor via different inlets, mixing same at a mixin...
|
|
WO/2022/237780A1 |
An amide derivative and the pharmaceutical use thereof, in particular, the present invention relates to an amide derivative of formula (I) or a pharmaceutically acceptable salt thereof or all stereoisomers, tautomers and deuterated compo...
|
|
WO/2022/229907A1 |
Compounds of formula (I) useful as antineoplastic and antimicrobial agents are disclosed Compositions and methods of using antineoplastic and antimicrobial compounds are disclosed.
|
|
WO/2022/214053A1 |
A compound of formula (I) as a USP1 inhibitor or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, and the use thereof in the prevention or t...
|
|
WO/2022/119823A1 |
Positive allosteric modulators (PAMs) of Mas-related G protein-coupled receptor X1 (MRGPRX1) and their use for treating neuropathic pain is disclosed.
|
|
WO/2022/109117A1 |
The present invention is directed to 3-amino pyrrolidine and piperidine macrocyclic compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treat...
|
|
WO/2022/056914A1 |
Provided is a refining method for acesulfame. The method comprises: adding hydrogen peroxide and activated carbon into an acesulfame-containing crude product solution, keeping same at a first preset temperature for a first preset time, a...
|
|
WO/2021/238587A1 |
A micromolecular oxathiazine derivative, which belongs to the field of organic synthesis medicines and has the general formula as shown below: the micromolecular oxathiazine derivative can be used as a positive allosteric modulator of an...
|
|
WO/2021/238588A1 |
An oxathiazine compound, of which the general formula is as follows. The oxathiazine compound can be used as a positive allosteric modulator of an AMPA receptor, and can positively modulate the AMPA receptor and make the conformation mor...
|
|
WO/2021/170913A1 |
Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic o...
|
|
WO/2021/143821A1 |
A fused heteroaryl derivative, a preparation method therefor, and an application thereof in medicine. In particular, provided are a fused heteroaryl derivative as shown in general formula (I-1), a preparation method therefor, a pharmaceu...
|
|
WO/2020/234828A1 |
A method of inhibiting GAPDH with certain oxathiazin-like compounds and/or related compounds.
|
|
WO/2020/094542A1 |
The invention relates to 5,6-diphenyl-5,6-dihydro- dibenz[c,e][1,2 ]azaphosphorin and 6-phenyl-6H-dibenzo[c,e] [1,2]thiazin-5,5 dioxide derivatives and similar compounds of the formula (1) as organic electroluminescent materials for use ...
|
|
WO/2020/046132A1 |
The present invention relates to therapeutic methods for the management of a patient's lysosomal storage disease by enzyme replacement therapy. The methods involve the use of combinations of, and kits containing: a) an exogenous lysosoma...
|
|
WO/2020/016434A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...
|
|
WO/2019/213987A1 |
Disclosed are a monophosphine ligand based on a tetramethyl spirobiindane skeleton and an intermediate thereof, and a preparation method therefor and the use thereof. The monophosphine ligand is a compound having the structure represente...
|
|
WO/2019/141369A1 |
The present invention generally relates to a process for the preparation of a product, the prod- uct being 6-methyl-3,4-dihydro1,2,3-oxathiazin-4-one 2,2-dioxide or a derivative thereof. The present invention also relates to the use of s...
|
|
WO/2019/114999A1 |
In general, the invention relates to a process for the preparation of acesulfame or a derivative thereof. More specifically, the invention relates to a process, to a product obtainable by the process and the use of a specified velocity o...
|
|
WO/2019/104199A1 |
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through ...
|
|
WO/2019/101132A1 |
Disclosed in the present invention are a fluorosulfonyl-containing compound, an intermediate thereof, a preparation method therefor and use thereof. The fluorosulfonyl-containing compound disclosed in the present invention comprises a ca...
|
|
WO/2019/104201A1 |
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through ...
|
|
WO/2019/095599A1 |
A photocrosslinked hydrogel material. The material is prepared by: dissolving a component A, a photosensitive polymer derivative, in a biocompatible medium to obtain a photosensitive polymer solution A; dissolving a component B, a photoi...
|
|
WO/2019/095600A1 |
Provided are preparation, raw materials, a product, and an application of a photocoupled synergistic crosslinked hydrogel material. The material is prepared by: dissolving a component A, a polymer derivative modified by an o-nitrobenzyl ...
|
|
WO/2019/094732A1 |
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating diseases associated with the binding of CREB to CREB-binding protein (CBP) and...
|
|
WO/2019/053617A1 |
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormµLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt ...
|
|
WO/2018/237145A1 |
The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease, mitchonodrial disease, fibrosis, and/or cardiomyopathy.
|
|
WO/2018/107112A1 |
Embodiments are directed to compounds of the formulae (I), (Ia), (Ib), (II), (IIa) (III), (IV), (V), and (VI); methods for treating cancer with one or more compounds of the formulae (I), (Ia), (Ib), (II), (IIa); (III), (IV), (V), and (VI...
|
|
WO/2018/057389A1 |
A process for producing acesulfame potassium, the process comprising the steps of providing a cyclizing agent composition comprising a cyclizing agent and a solvent and having an initial temperature, cooling the cyclizing agent compositi...
|
